


JFW



ATTORNEY DOCKET NO. 13099.0023U2
APPLICATION NO. 10/827,111

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

TACHDJIAN *et al.*

Application No. 10/827,111

Filed: April 19, 2004

FOR: "SUBSTITUTED DIHYDRONAPHTHALENE
AND ISOCHROMAN COMPOUNDS FOR THE
TREATMENT OF METABOLIC DISORDERS,
CANCER AND OTHER DISEASES"

)
)
) Confirmation No: 1476
)
) Group Art: 1625
)
) Examiner: Covington, Raymond K.
)
)
)
)
)
)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer No. 23859

September 12, 2005

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents recently first cited in communications from foreign patent offices in related applications. A copy of each of the two foreign patent documents is enclosed, and the equivalent English language U.S. Patent equivalent of one of the cited PCT publications is also cited on the list. In accordance with 37 C.F.R. § 1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(c), in that neither a final Office Action nor a Notice of Allowance has been mailed to Applicants. Accordingly, Applicants make the statement required under 37 C.F.R. § 1.97(c)(1).

The undersigned hereby certifies that each item of foreign patent information contained in the Information Disclosure Statement List was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. U.S. Patent No. 6,927,228 was not cited in a communication from a foreign patent office in a counterpart foreign application, but came to the attention of the undersigned as a result of the above-mentioned communications, therefore U.S. Patent No. 6,927,228 was unknown to any individual designated in 35 U.S.C. §1.56 (c) more than three months prior to the filing of this information disclosure statement.


Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

NEEDLE & ROSENBERG, P.C.
Customer No. 23859
(678) 420-9300 Phone
(678) 420-9301 Fax


Mark A. Murphy, Ph.D.
Registration No. 42,915

CERTIFICATE OF MAILING

I hereby certify that this correspondence and any documents referenced herein as being enclosed herein are being deposited with the United States Postal Service in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below.


Mark A. Murphy, Ph.D.


Date



ATTORNEY DOCKET NO. 13099.0023U2
APPLICATION NO. 10/827,111
SHEET 1 OF 1

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/827,111
Filing Date	April 19, 2004
First Named Inventor	TACHDJIAN <i>et al.</i>
Group Art Unit	1625
Examiner Name	Covington, Raymond K.

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	C1	US-6,927,228 B2	08/09/2005	Bernardon <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes No
	C2	WO 02/12210	02/14/2002	Galderma Research and Development (<i>See</i> US-6,927,228 B2) (English translation)	X
	C3	WO 00/63196	10/26/2000	Novo Nordisk A/S	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.